Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.

The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) as treatment for people with HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence.

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer. | An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis' Kisqali and Eli Lilly's Verzenio in early breast cancer.

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a high risk of recurrence.

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine therapy.

Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.

Women with early-stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment, drug maker Novartis announced Tuesday.